Rep. Julia Letlow Unloads Icon Plc (NASDAQ:ICLR) Stock

Posted by Grant Hamersma on Mar 25th, 2026

Representative Julia Letlow (Republican-Louisiana) recently sold shares of Icon Plc (NASDAQ:ICLR). In a filing disclosed on March 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Icon stock on February 12th. The trade occurred in the Representative’s “MERRILL LYNCH INVESTMENT ACCOUNT #025” account.

Representative Julia Letlow also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of Travelers Companies (NYSE:TRV) on 2/20/2026.
Sold $1,001 – $15,000 in shares of BXP (NYSE:BXP) on 2/20/2026.
Sold $1,001 – $15,000 in shares of HF Sinclair (NYSE:DINO) on 2/20/2026.
Purchased $1,001 – $15,000 in shares of Vistra (NYSE:VST) on 2/17/2026.
Sold $1,001 – $15,000 in shares of Public Service Enterprise Group (NYSE:PEG) on 2/17/2026.
Sold $1,001 – $15,000 in shares of Expand Energy (NASDAQ:EXE) on 2/17/2026.
Sold $1,001 – $15,000 in shares of Take-Two Interactive Software (NASDAQ:TTWO) on 2/12/2026.
Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 2/12/2026.
Sold $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 2/12/2026.
Purchased $1,001 – $15,000 in shares of Regeneron Pharmaceuticals (NASDAQ:REGN) on 2/12/2026.

Icon Price Performance

Shares of NASDAQ ICLR opened at $101.28 on Wednesday. The business has a 50 day simple moving average of $131.28 and a 200-day simple moving average of $161.55. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00. The company has a market capitalization of $8.18 billion, a price-to-earnings ratio of 13.71, a price-to-earnings-growth ratio of 2.57 and a beta of 1.35. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31.

Analyst Upgrades and Downgrades

ICLR has been the topic of several research reports. Leerink Partners reiterated a “market perform” rating and set a $105.00 price objective on shares of Icon in a research note on Thursday, February 12th. BMO Capital Markets reaffirmed a “market perform” rating and set a $100.00 target price on shares of Icon in a report on Thursday, February 12th. Mizuho set a $216.00 price target on Icon in a research report on Friday, January 9th. Truist Financial restated a “hold” rating and set a $222.00 price objective (down from $231.00) on shares of Icon in a research report on Thursday, January 8th. Finally, Barclays dropped their target price on Icon from $200.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Monday, March 9th. Six analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $146.80.

Check Out Our Latest Research Report on ICLR

Hedge Funds Weigh In On Icon

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Artisan Partners Limited Partnership increased its position in Icon by 67.4% in the 2nd quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock valued at $1,045,039,000 after acquiring an additional 2,893,946 shares during the period. Principal Financial Group Inc. boosted its position in Icon by 739.2% during the 3rd quarter. Principal Financial Group Inc. now owns 3,277,293 shares of the medical research company’s stock worth $573,526,000 after acquiring an additional 2,886,755 shares during the period. Harris Associates L P bought a new position in shares of Icon in the second quarter worth $238,256,000. Capital World Investors increased its holdings in shares of Icon by 555.2% during the fourth quarter. Capital World Investors now owns 1,496,479 shares of the medical research company’s stock valued at $272,688,000 after purchasing an additional 1,268,095 shares during the period. Finally, Norges Bank acquired a new position in shares of Icon during the second quarter valued at $158,639,000. 95.61% of the stock is owned by institutional investors.

About Representative Letlow

Julia Letlow (Republican Party) is a member of the U.S. House, representing Louisiana’s 5th Congressional District. She assumed office on April 14, 2021. Her current term ends on January 3, 2027.

Letlow (Republican Party) is running for re-election to the U.S. House to represent Louisiana’s 5th Congressional District. She declared candidacy for the primary scheduled on November 3, 2026.

Julia Letlow earned a doctorate. Letlow’s career experience includes working as a senior administrator with the University of Louisiana at Monroe.

About Icon

(Get Free Report)

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.